PT  - JOURNAL ARTICLE
AU  - Stefano Serra
AU  - Runjan Chetty
TI  - Rnf43
AID  - 10.1136/jclinpath-2017-204763
DP  - 2018 Jan 01
TA  - Journal of Clinical Pathology
PG  - 1--6
VI  - 71
IP  - 1
4099  - http://jcp.bmj.com/content/71/1/1.short
4100  - http://jcp.bmj.com/content/71/1/1.full
SO  - J Clin Pathol2018 Jan 01; 71
AB  - RNF43 (E3 ubiquitin-protein ligase RNF43 or RING-type E3 ubiquitin transferase RNF43) functions as a tumor suppressor, by exerting a predominant negative feedback mechanism in the Wnt/β-catenin signaling pathway. RNF43 inhibits Wnt/beta-catenin signaling by ubiquitinating Frizzled receptor and targeting it to the lysosomal pathway for degradation. Loss of function of RNF43 results in decrease/lack of degradation of Frizzled with enhancement of Wnt/β-catenin signaling pathway. Mutations of RNF43 have been reported in different cancers. We describe the structure of RNF43, its function and most frequent mutations in different cancers.